Pediatr Infect Dis J . Use of Sotrovimab in 14 Children with COVID-19: A Single-Center Experience

[tetano]

Pediatr Infect Dis J


. 2022 Nov 29.
doi: 10.1097/INF.0000000000003781. Online ahead of print.
Use of Sotrovimab in 14 Children with COVID-19: A Single-Center Experience


Sarina Kim Butzer ¹ , Sandra Habbig ² , Katrin Mehler ¹ , Sophie Haumann ² , Meike Meyer ³ , Norma Jung ⁴ , André Oberthür ¹



Affiliations

• PMID: 36730080
• DOI: 10.1097/INF.0000000000003781

Abstract

Children affected by coronavirus disease 2019 (COVID-19) with preexisting comorbidities are at risk of complications. Monoclonal antibodies prevent severe COVID-19 courses in adults but data on children are scarce. Here we report on the use of Sotrovimab in 14 children at risk of severe disease treated at the University of Cologne Children's Hospital. Tolerability was good and no infusion-related reactions were seen.